Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
20 participants
INTERVENTIONAL
2006-05-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Bevacizumab for Age-Related Macular Degeneration
NCT00347165
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
NCT00407121
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
NCT00599820
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
NCT00347399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal injection of Bevacizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
* Active angiogram leakage
Exclusion Criteria
* Endoftalmitis history
* Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
60 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación para Evitar la Ceguera en México
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Veronica Kon-Jara, MD
Role: PRINCIPAL_INVESTIGATOR
Asociación para Evitar la Ceguera en México
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asociacion para Evitar la Ceguera en Mexico
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APEC-0012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.